AZD 3342
Alternative Names: AZD3342Latest Information Update: 19 Feb 2007
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 01 Feb 2007 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
- 28 Jun 2006 AstraZeneca has completed a phase I trial in Chronic obstructive pulmonary disease in the United Kingdom
- 27 Jan 2005 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route)